Analysis of prothrombin time prolongation in North American cefotetan clinical trials: questions and answers.
Goldstein
N H
NH
Division of Clinical and Medical Affairs, Stuart Pharmaceuticals, Wilmington, Delaware 19897.
D015313:Cefotetan; D002440:Cefoxitin / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology; D002513:Cephamycins / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D006801:Humans; D007020:Hypoprothrombinemias / Q000139:chemically induced*; D009070:Moxalactam / Q000494:pharmacology; D011517:Prothrombin Time
D002513:Cephamycins; D015313:Cefotetan; D002440:Cefoxitin; D002443:Ceftriaxone; D009070:Moxalactam